Skip to content

Clinical study on the treatment of antibiotic-refractory recurrent urinary tract infections in postmenopausal women with "Cocktail Therapy"

Clinical study on the treatment of antibiotic-refractory recurrent urinary tract infections in postmenopausal women with "Cocktail Therapy"

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102990
Enrollment
Unknown
Registered
2025-05-22
Start date
2025-05-23
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent urinary tract infections

Interventions

Menopausal women with a diagnosis of antibiotic-refractory recurrent urinary tract infection: "Cocktail Therapy"

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Menopausal women with a diagnosis of antibiotic-refractory recurrent urinary tract infection. Diagnostic criteria are: symptomatic urinary tract infection confirmed by at least 3 urine cultures within 1 year or at least 2 urine cultures within 6 months prior to receiving treatment. Urine culture: positive for one known uropathogen >1000 cfu/ml and allergy or resistance to 3 or more antibiotics. Symptoms: at least three lower urinary tract symptoms, including urinary frequency, urgency, dysuria, hematuria, dysuria, and lower abdominal pain.

Exclusion criteria

Exclusion criteria: 1. Known urologic tumors , stones and congenital or acquired genitourinary tract abnormalities; 2.Prolonged indwelling urinary catheter, or neurogenic bladder requiring intermittent catheterization; 3. Residual urine volume >100ml; 4.Uncontrolled diabetes mellitus; 5. Steroidal corticosteroids being applied; 6. Immunosuppressive disease; 7.History of any sex hormone replacement therapy in the previous year; 8.Known or suspected sex hormone-dependent malignancy or any other active malignancy; 9. Unexplained vaginal bleeding; 10. Active or recent thromboembolic disease; 11.Presence of contraindications to sodium hyaluronate infusion; 12. Severe hepatic or renal function abnormalities; 13.Unwillingness to accept treatment, inability to understand the treatment regimen, or refusal to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Interval between treatment and 1st relapse (days);Number of recurrences of urinary tract infections during the 1-year follow-up period (times/year);

Secondary

MeasureTime frame
Need for antibiotic therapy during follow-up (drugs and duration);Pelvic pain-urinary urgency-frequent urination ;Quality of Life ;

Countries

China

Contacts

Public ContactDeyi Luo

West China Hospital, Sichuan University

luodeyi@scu.edu.cn+86 189 8060 6809

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026